What Sorriso Pharmaceuticals does

Sorriso Pharmaceuticals (legal entity Sorriso Pharma Inc., Utah) is a privately held, clinical-stage biotechnology company founded in 2020 that develops orally delivered antibody therapeutics for immune-mediated diseases, with headquarters in Sandy, UT and laboratory operations at Magnify at CNSI at UCLA in Los Angeles, CA. The company's work is built on its proprietary Vorabody platform, which engineers single-domain antibodies designed to maintain potency and specificity within inflamed intestinal tissue while remaining stable at room temperature and manufacturable via scalable yeast fermentation. The lead candidate, SOR102, is an oral bispecific anti-TNFα/anti-IL-23 Vorabody for inflammatory bowel disease that completed a positive Phase 1b trial in ulcerative colitis, with data published in The Lancet Gastroenterology & Hepatology and presented at ECCO 2025 and UEG 2025. Two additional programs, SOR101 (oral anti-TNFα for immune checkpoint inhibitor mediated colitis) and SOR104 (anti-IL-7Rα deliverable orally to GI tissue or by inhalation for pulmonary disease such as asthma), extend the platform across adjacent indications.

Sorriso is pre-revenue and generates no commercial product sales; future revenue is expected to come from commercialization of oral antibody therapeutics for immune-mediated diseases, primarily inflammatory bowel disease (IBD). The company was capitalized with a $31 million Series A in December 2021 co-led by New Enterprise Associates (NEA) and Arix Bioscience, followed by an SEC Form D filing in January 2022 targeting approximately $31.39 million. The go-to-market model for SOR102 will target gastroenterologists and IBD specialists through traditional pharmaceutical specialty distribution once regulatory approval is obtained, with current commercial activity limited to peer-reviewed publications and presentations at major gastroenterology conferences (ECCO, UEG, DDW) to build clinical credibility.

Sorriso's customer base is the patient population with immune-mediated diseases — principally IBD (Crohn's disease and ulcerative colitis) — and the prescribing gastroenterologists and IBD specialists who manage them; the company also addresses the niche oncology-adjacent segment of immune checkpoint inhibitor mediated colitis through SOR101 and, via SOR104, T cell mediated pulmonary diseases such as asthma. Investors include NEA, Arix Bioscience, Pappas Capital, and Biovision Ventures, and the leadership team is anchored by founder, President, and CEO Ciara Kennedy.

Name

Sorriso Pharmaceuticals

Legal name

Sorriso Pharma Inc.

Website

https://sorrisopharma.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Sorriso Pharmaceuticals is a clinical-stage biotech developing orally delivered, single-domain antibody therapeutics (Vorabody platform) for immune-mediated diseases, with lead candidate SOR102 (oral anti-TNFα/anti-IL-23 bispecific) in Phase 1b for inflammatory bowel disease, serving IBD patients and gastroenterologists.

Ownership category

akta.pro rank

Product category

Oral Antibody Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Oral antibody therapeutics
• Inflammatory bowel disease
• Single domain antibodies
• Bispecific antibody drugs
• Immune mediated disease therapies

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure

Revenue model

1. Pharmaceutical product sales: Pre-revenue company. Future revenue expected from commercialization of oral antibody therapeutics for immune-mediated diseases, primarily inflammatory bowel disease (IBD). The company is in clinical development stage with lead candidate SOR102.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Sorriso Pharmaceuticals develops a pipeline of orally delivered antibody therapeutics built on its proprietary Vorabody platform for the treatment of immune-mediated inflammatory diseases. The lead program, SOR102, is an oral anti-TNFα/anti-IL-23 bispecific in Phase 1b development for inflammatory bowel disease, accompanied by SOR101 (oral anti-TNFα for immune checkpoint inhibitor-mediated colitis) and SOR104 (anti-IL-7Rα for GI and pulmonary indications). The platform enables single-domain antibodies to be dosed orally, penetrate inflamed tissue, and engage their targets locally with minimal systemic exposure.

Product overview

Sorriso Pharmaceuticals is a biopharmaceutical company advancing a pipeline of novel oral antibodies built on its proprietary Vorabody platform. The company's portfolio includes three core programs: SOR101 (oral anti-TNFa for immune checkpoint inhibitor mediated colitis), SOR102 (oral bispecific anti-TNF/anti-IL-23 for inflammatory bowel disease), and SOR104 (oral/inhaled anti-IL-7Ra for GI and pulmonary diseases). All programs leverage the Vorabody platform's unique single-domain antibody engineering that enables oral delivery and tissue localization within inflamed tissue, offering potential alternatives to injectable therapies for immune-mediated diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• SOR101 Program Clinical development-stage oral anti-TNFα antibody program based on the Vorabody platform, designed to treat immune checkpoint inhibitor (ICI) mediated colitis (IMC) by reaching inflamed intestinal mucosa and engaging its target after oral dosing in humans.
• SOR102 Program Lead clinical-stage oral bispecific antibody combining anti-TNFα and anti-IL-23 Vorabodies into a single dual-acting molecule for inflammatory bowel disease (IBD). A trypsin-cleavable linker releases monomers to independently engage TNFα and IL-23 throughout intestinal tissue, providing combination therapy locally within inflamed tissue with minimal systemic immunosuppression risk. SOR102 completed Phase 1b with positive safety, pharmacokinetics, and efficacy results announced in December 2024.
• SOR104 Program Anti-IL-7Rα Vorabody program that blocks IL-7 and TSLP-mediated signaling. Can be dosed orally to reach gastrointestinal tissue or inhaled to treat pulmonary diseases such as asthma, providing a dual-mechanism, local-delivery therapeutic platform for T cell mediated diseases.

Quantifiable outcome

• Phase 1b trial showed positive safety, pharmacokinetics, and efficacy data for SOR102 in ulcerative colitis patients
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• AbbVie: Markets Humira (anti-TNF), Skyrizi (anti-IL-23) and Rinvoq (JAK inhibitor) for IBD. Direct competitive incumbent across both of SOR102's target pathways and the primary benchmark SOR102 must beat on efficacy, safety and access.
• Johnson & Johnson (Janssen): Markets Stelara (anti-IL-12/23) and Tremfya (anti-IL-23) in IBD. Directly competes with SOR102 on the IL-23 pathway and represents the kind of large-pharma incumbent Sorriso must displace or partner with.
• Takeda Pharmaceutical: Markets Entyvio (vedolizumab), a gut-selective anti-α4β7 integrin biologic for UC and Crohn's. Most direct mechanistic analog to Sorriso's gut-restricted approach, making Takeda a key strategic and competitive reference point.
• Eli Lilly: Develops mirikizumab (anti-IL-23) in IBD and is a leader in immunology biologics. Represents large-pharma competition on the IL-23 axis and a likely strategic acquirer or partner for differentiated IBD assets.
• Bristol Myers Squibb: Markets Zeposia (ozanimod, oral S1P modulator) in UC. Represents the leading oral small-molecule IBD franchise and the most direct comparator to the patient-experience value proposition Sorriso is targeting.

Emerging players

• Morphic Holding: Developed oral integrin inhibitors for IBD (e.g., MORF-057), the most direct emerging oral-modality competitor to Sorriso's oral approach in the same disease. Most relevant emerging peer given overlapping therapeutic area and oral strategy.
• Prometheus Biosciences: IBD-focused biotech (acquired by Merck in 2023) that advanced targeted therapies for UC and Crohn's. Highly comparable clinical-stage peer that exited via strategic acquisition — a relevant benchmark for Sorriso's M&A trajectory.
• Landos Biopharma: Clinical-stage immunology biotech developing oral therapeutics for UC and other autoimmune diseases. Comparable as a small-cap, oral, IBD-focused biotech with platform-based pipeline economics.
• AbCellera Biologics: Antibody discovery and engineering platform company with bispecific and single-domain antibody programs. Comparable on the antibody-engineering platform axis relevant to Vorabody technology, though broader in indication scope.
• Adagene: Clinical-stage biotech developing precision antibody therapeutics including bispecifics. Comparable on bispecific antibody engineering and clinical-stage immunology positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sorrisopharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sorriso Pharmaceuticals